Pairing Zymeworks’ Topoisomerase 1-inhibitor Linker-Payload with the Appropriate ADC Target, Antigen, & Indication

Time: 11:45 am
day: Day One


  • Zymeworks is focused on applying its ADC technologies for the treatment of patients suffering from diseases with high unmet need
  • Integrated consideration of the antibody, linker-payload, indication, and target compatibility are important in the design of antibody drug conjugates
  • Factors considered in the design of Zymeworks’ Topoisomerase 1-inhibitor ADC candidates ZW191, ZW220 and ZW251 will be reviewed